Resistant Cancer
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Lorlatinib Combinations in Lung Cancer (NCT04292119) | Massachusetts General Hospital | 2020-05-01 |
| 9-ING-41 in Patients With Advanced Cancers (NCT03678883) | Actuate Therapeutics Inc. | 2019-01-04 |
Track Resistant Cancer automatically
Every clearance here is in the API, with alerts when new ones post.